Status:
RECRUITING
Comparison of the Healing Properties on Corneal Cells of Groth Factor-enriched Plasma and Autologous Serum From Aniridia Patients
Lead Sponsor:
Fondation Ophtalmologique Adolphe de Rothschild
Conditions:
Aniridia
Eligibility:
All Genders
18+ years
Brief Summary
Keratopathy of patients with aniridia leads to epithelial scarring disorders and a progressive clouding of the cornea linked to this abnormal healing (fibrosis). Treatment with autologous serum is usu...
Detailed Description
Blood collection from aniridia patients and healthy controls, half of which will be used to make autologous serum and the other half to make growth factor rich plasma, used for in vitro studies. A co...
Eligibility Criteria
Inclusion
- For patients with aniridia:
- With aniridia
- Patient weighing more than 43 kg
- If the patient is being treated with autologous serum, a delay of 8 weeks after the last blood collection
- If a blood donation has been made, a delay of 8 weeks must be respected after the last donation
- For controls:
- Non-aniridia (no clinical signs)
- Weighing more than 43 kg
- Matched to a case for sex and age +/-10 years
- No known diabetes
- If a blood donation has been made, a delay of 8 weeks must be respected after the latter
Exclusion
- Insufficient sample volume
- No conjunctival print
- HBV, HCV, HIV serology positive
- Aniridia not genetically confirmed for cases For each patient excluded, a new patient will be included in order to maintain the number of patients required for data analysis.
Key Trial Info
Start Date :
May 15 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT05400590
Start Date
May 15 2023
End Date
May 1 2026
Last Update
December 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Fondation A. de Rothschild
Paris, France, 75019